News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,202 Results
Type
Article (8016)
Company Profile (142)
Press Release (478313)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166712)
Career Advice (303)
Deals (25738)
Drug Delivery (7)
Drug Development (52796)
Employer Resources (14)
FDA (9749)
Job Trends (8570)
News (238056)
Policy (17880)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (491)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33140)
ALS (114)
Alzheimer's disease (989)
Antibody-drug conjugate (ADC) (290)
Approvals (10417)
Artificial intelligence (341)
ASCO (159)
Autoimmune disease (226)
Automation (30)
Bankruptcy (263)
Belgium (3)
Best Places to Work (6952)
BIO (36)
Biologics (10)
BIOSECURE Act (1)
Biosimilars (118)
BioSpace Insights (17)
Biotechnology (90)
Bispecific (2)
Bladder cancer (140)
Brain cancer (33)
Breast cancer (522)
Cancer (3812)
Cardiovascular disease (228)
Career advice (242)
Career pathing (1)
CAR-T (181)
CDC (1)
CDMO (21)
Celiac Disease (1)
Cell therapy (495)
Cervical cancer (35)
Clinical research (48060)
Collaboration (1295)
Commercialization (3)
Compensation (1544)
Complete response letters (35)
COVID-19 (761)
CRISPR (64)
C-suite (818)
Cystic fibrosis (87)
Data (5954)
Denatured (4)
Depression (107)
Dermatology (74)
Diabetes (363)
Diagnostics (4226)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (161)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (168)
Earnings (73763)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88192)
Executive appointments (721)
FDA (12530)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (24)
Funding (967)
Gene editing (126)
Generative AI (11)
Gene therapy (337)
GLP-1 (297)
Government (944)
Grass and pollen (2)
Guidances (281)
Healthcare (9364)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (70)
Immunology and inflammation (108)
Immuno-oncology (62)
Indications (168)
Infectious disease (954)
Inflammatory bowel disease (131)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (266)
Interviews (41)
IPO (12389)
IRA (2)
Job creations (1967)
Job search strategy (232)
JPM (1)
Kidney cancer (17)
Kidney disease (46)
Layoffs (59)
Legal (5194)
Licensing (22)
Liver cancer (46)
Longevity (20)
Lung cancer (552)
Lymphoma (261)
Machine learning (29)
Management (3)
Manufacturing (584)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8682)
Medtech (8844)
Mergers & acquisitions (14419)
Metabolic disorders (738)
mRNA (69)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (229)
Neuropsychiatric disorders (40)
Neuroscience (1887)
NextGen: Class of 2026 (3147)
Non-profit (843)
Obesity (235)
Opinion (10)
Ovarian cancer (164)
Pain (179)
Pancreatic cancer (209)
Parkinson's disease (208)
Partnered (12)
Patents (508)
Patient recruitment (534)
Patient selection (11)
Peanut (32)
People (41395)
Peptides (3)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15525)
Phase 2 (21467)
Phase 3 (14479)
Pipeline (7889)
Policy (18)
Postmarket research (1559)
Preclinical (6559)
Press Release (34)
Prostate cancer (193)
Psychedelics (9)
Radiopharmaceuticals (196)
Rare diseases (598)
Real estate (3023)
Recruiting (6)
Regenerative medicine (5)
Regulatory (15005)
Reports (23)
Research institute (585)
Resumes & cover letters (45)
Rett syndrome (43)
RNA editing (6)
RSV (48)
Schizophrenia (104)
Series A (167)
Series B (124)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (91)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (51)
Vaccines (321)
Venture capital (17)
Weight loss (75)
Women's health (91)
Date
Today (99)
Last 7 days (315)
Last 30 days (1554)
Last 365 days (19089)
2026 (14105)
2025 (19251)
2024 (22974)
2023 (26529)
2022 (34586)
2021 (37150)
2020 (33468)
2019 (23256)
2018 (17468)
2017 (18744)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18127)
2012 (20202)
2011 (20440)
2010 (20332)
Location
Africa (227)
Alabama (80)
Alaska (2)
Arizona (313)
Arkansas (10)
Asia (17964)
Australia (2094)
California (12480)
Canada (3275)
China (556)
Colorado (507)
Connecticut (434)
Delaware (218)
Europe (24651)
Florida (1875)
Georgia (395)
Hawaii (3)
Idaho (46)
Illinois (739)
India (54)
Indiana (326)
Iowa (16)
Japan (433)
Kansas (104)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1239)
Massachusetts (8165)
Michigan (315)
Minnesota (575)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (124)
New Hampshire (60)
New Jersey (2734)
New Mexico (12)
New York (2926)
North Carolina (1323)
North Dakota (4)
Northern California (6278)
Ohio (298)
Oklahoma (14)
Oregon (16)
Pennsylvania (2320)
Puerto Rico (24)
Rhode Island (30)
South America (402)
South Carolina (78)
South Dakota (1)
Southern California (5204)
Tennessee (125)
Texas (2040)
United States (40437)
Utah (377)
Vermont (1)
Virginia (159)
Washington D.C. (39)
Washington State (963)
West Virginia (1)
Wisconsin (78)
Wyoming (1)
486,202 Results for "genvivo inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
September 11, 2025
·
5 min read
Press Releases
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2025
·
6 min read
Drug Development
GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib Clinical Trial Evaluating GEN2, a Personalizing, Gene Vector Immunotherapy, in Patients with Advanced Solid Tumors
GenVivo, Inc. announced that it has dosed the first US patient in a Phase I/Ib, open-label, dose-escalation and expansion clinical trial of GEN2.
June 27, 2024
·
5 min read
Press Releases
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
May 14, 2025
·
5 min read
Press Releases
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 28, 2025
·
5 min read
Press Releases
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 11, 2024
·
5 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Press Releases
Allumiqs Solutions Inc. and Allumiqs Corporation
September 15, 2026
·
1 min read
Press Releases
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027
September 29, 2026
·
8 min read
Press Releases
Carlsmed, Inc. Announces Chief Operating Officer Appointment
September 8, 2026
·
2 min read
1 of 48,621
Next
